- Home
- NPCE vs TNGX Comparison
NPCE vs TNGX Comparison
Compare NPCE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPCE | TNGX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.8M | 1.4B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NPCE | TNGX |
|---|---|---|
| Price | $16.29 | $9.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $17.29 | $12.50 |
| AVG Volume (30 Days) | 248.7K | ★ 2.6M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $94,864,000.00 | $66,501,000.00 |
| Revenue This Year | $24.82 | $53.01 |
| Revenue Next Year | $1.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.08 | ★ 53.29 |
| 52 Week Low | $7.56 | $1.03 |
| 52 Week High | $18.98 | $11.20 |
Technical Indicators
Market Signals| Indicator | NPCE | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 52.39 |
| Support Level | $16.00 | $8.89 |
| Resistance Level | $16.94 | $10.22 |
| Average True Range (ATR) | 0.80 | 0.63 |
| MACD | -0.11 | -0.14 |
| Stochastic Oscillator | 68.23 | 20.91 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.